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Tolerance that develops after chronic morphine exposure has been proposed to be an
adaptive response that develops and decays over a deﬁned time course.The present study
examined the development of tolerance to the acute hypothermic and analgesic effects of
morphine and correlated the time course for the desensitization in vivo with the reduced
responsiveness to DAMGO and 2-CADO and increased responsiveness to nicotine of the
longitudinal muscle/myenteric plexus (LM/MP) preparation in vitro. Assessment was per-
formed at various times after morphine or placebo pellet implantation. Morphine produced
a modest hypothermic response to which no tolerance developed. However, the devel-
opment of tolerance to the analgesic effect of morphine, the inhibitory effect of DAMGO
and CADO on neurogenic twitches of the LM/MP and hypersensitivity to the contractile
response to nicotine was observed to occur in a time-dependent manner. The alterations
in sensitivity to DAMGO, nicotine, and responsiveness to morphine analgesia occurred
between days 4 and 10 and returned to normal by day 14 post-implantation. In contrast,
sensitivity of LM/MP preparations to 2-CADO displayed a similar time-dependent onset
but the tolerance persisted beyond 14 days after implantation.These data suggest that the
heterologous tolerance that develops after chronic morphine treatment is time-dependent
and persistent but, ultimately returns to normal in the absence of any intervention. Further-
more, the data suggest that the basis of the adaptive phenomenon may involve multiple
cellular mechanisms including the modulation of cell excitability and normal physiology but
the consequences of the adaptation extend to all effects of the agonist.
Keywords: morphine tolerance, longitudinal muscle/myenteric plexus, analgesic tolerance, guinea pig,
hypothermia, adaptation, opioid receptors, nicotinic receptors
INTRODUCTION
The use of opioids is associated with the development of toler-
ance, the extent which varies depending on the pharmacological
effect. In humans, tolerance has been observed to various pharma-
cological effects of morphine like analgesia and euphoria whereas
tolerance to miosis, respiration depression, and its constipating
effect does not seem to be evident. Cellularmechanisms associated
with the development of tolerance to opioids in animal mod-
els and humans include but not limited to kinase-related (PKA,
PKC, and G protein-coupled receptor kinase) phosphorylation of
the receptor and other cellular proteins, beta-arrestin-facilitated
downregulation of the receptor, alteration of endogenous ligand
levels, changes in restingmembrane potential, and cAMP superac-
tivation (Connor et al., 2004). However, the extent to which each
or all of these potential mechanisms contributes to the ﬁnal phe-
notype and whether the type of tolerance observed in one tissue
or model system is also observed in all the systems where the ago-
nist exerts an action has not been adequately explored. Though
cellular adaptation observed in the development of tolerance does
not appear to be similar in different cells/tissues/systems, it has
been observed that the time course for the appearance and dis-
appearance of the altered sensitivity may be comparable for some
pharmacological effects (Li et al., 2010).
Opioid tolerance in the guinea longitudinal muscle/myenteric
plexus (LM/MP) is associated with the development of non-
speciﬁc supersensitivity to excitatory agonists (Schulz and Gold-
stein, 1973; Johnson et al., 1978) and non-speciﬁc subsensitivity to
inhibitory agents (Taylor et al., 1988; Leedham et al., 1992) that has
been related to a partialmembranedepolarizationof themyenteric
“S” neurons (Li et al., 2010). In addition, it appears that there may
be an association between the time course over which the change
in responsiveness and the reduction in the abundance of the alpha3
subunit of the Na+/K+ ATPase occurs in the LM/MP model (Li
et al., 2010). However, no studies have determined whether the
time course for thedevelopmentof tolerance in vivo correlateswith
the time course observed for the loss of responsiveness and devel-
opment of enhanced responsiveness to nicotine of the LM/MP
in vitro. Indeed, the studies that investigated the enhanced respon-
siveness to excitatory substances only evaluated the responsiveness
7 days after morphine pellet implantation but did not explore any
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other time periods (Schulz and Goldstein, 1973; Johnson et al.,
1978).
We previously demonstrated, in longitudinal studies over a
span of 21 days, that chronic in vivo treatment with morphine
using different treatment paradigms results in the development
of quantitatively and qualitatively similar heterologous toler-
ance in the guinea LM/MP preparation that was ﬁrst observed
between 4 and 7 days, and disappeared by day 14 (Li et al., 2010).
We have also previously shown that chronic parenteral treat-
ment with morphine leads to the development of tolerance to
the analgesic effects of acute morphine (Maguma and Taylor,
2011) but did not determine whether similar tolerance devel-
oped after pellet implantation or explore the time course over
which the change occurred. The goal of the present study was
to test the hypothesis that chronic in vivo exposure to opioids
through pellet implantation would produce a qualitatively simi-
lar progression in the appearance, maintenance, and disappear-
ance of enhanced sensitivity to excitatory and reduced sensitivity
to inhibitory agents in the LM/MP, and to the analgesic and
hypothermic effect of morphine in vivo. A corollary hypothe-
sis to be tested was that the time course over which tolerance
developed in these in vivo and in vitro models would be similar
and point to a non-speciﬁc mechanism underlying the develop-
ment of opioid tolerance that would be consistent with a general
change in cellular excitability across different tissues express-
ing the mu-opioid receptor. To this end, we have investigated
and compared the time course for the alteration in sensitiv-
ity to inhibitory (DAMGO and 2-chloroadenosine [2-CADO])
and the excitatory agent nicotine in the longitudinal muscle–
myenteric plexus (LM/MP) preparation and the changes in the
response of the animal to the analgesic and hypothermic effects of
morphine.
MATERIALS AND METHODS
SUBJECTS
All experimental procedures employing animals were reviewed
and approved by the Institutional Animal Care and Use Commit-
tee of the Brody School of Medicine at East Carolina University
and were conducted in accordance with the guidelines for the
humane use of animals in research [NIH “Public Health Service
Policy on Humane Care and Use of Laboratory Animals” (revised
2002)]. Dunkin–Hartley guinea pigs (Charles-River labs; Raleigh,
NC,USA) of either sex weighing 200–450 g were used in the study.
The animals were housed two per cage with access to food and
water ad libitum. The guinea pigs were kept in the animal facil-
ity for 1week to permit acclimation prior to initiation of the
treatment. Every effort was made to reduce the use of animals
to the minimum number required to achieve sufﬁcient statistical
power.
PROCEDURES
Morphine pellet implantation
Guinea pigs were anesthetized with isoﬂurane, administered by
inhalation, and one morphine- or lactose-containing pellet per
100 g of body weight was implanted subcutaneously in the ﬂank.
The animals were allowed to recover then returned to the animal
facility until the day of the experiment.
Longitudinal smooth muscle/myenteric plexus preparations
TheLM/MP fromtreated animalswas removed and isolated as pre-
viously (Taylor et al., 1988). Segments of the ileum were obtained
from animals sacriﬁced by decapitation following isoﬂurane anes-
thesia. The abdomen was opened to expose the cecum. The 10 cm
section of ileum closest to the cecum was removed and discarded,
and 2–4 cm segments of ilea from the adjacent 10 cm of ileum
were used for the LM/MP preparations. The segments of ilea were
threaded onto a glass rod and, using a cotton swab moistened
with Krebs–Henseleit solution, the LM/MP was carefully stripped
tangentially from the point of mesenteric attachment until the
muscle–nerve preparation was detached from the total area of the
ileum.
The resulting sheet of LM/MP was tied at each end with a ﬁne
thread, passed through platinum-ring electrodes, and placed in a
10-ml organ bath containing Krebs buffer solution. One thread
was tied to a Grass FT.03 force transducer and the other ﬁxed to
a tissue holder. The output of the force transducer was delivered
to a computer and digitized using the PowerLab/Chart 5 com-
puter program (AD Instruments, Colorado Springs, CO, USA)
through a four channel power lab system using a four chan-
nel Quad bridge converter interface (AD instruments, Colorado
Springs, CO, USA).
The tissues were maintained at 37˚C in a physiological Krebs
buffer solution bubbled continuously with a mixture of 95%
O2/5% CO2 consisting of the following (in mM): NaCl (117), KCl
(4.7),CaCl2 (2.5),KH2PO4 (1.2),MgSO4 (1.2),NaHCO3 (25), and
Dextrose (11.5). A basal tension of 1.0 g was set for each tissue and
isometric tension generated by themuscle was recorded and stored
using the PowerLab/Chart 5 program. Neurogenic contractions
were elicited via electrical stimulation using supramaximal voltage
delivered to the tissue through platinum-ring electrodes using a
stimulation system consisting of a Grass S48 stimulator connected
to the electrodes by a Med Lab Attenuator and Stimu-splitter. To
ensure only nerve endings were stimulated, the following parame-
ters were used: voltage (50V); impulse duration (<1ms); delay
setting (zero); and frequency (0.1Hz).
During the initial 1 h equilibration period, the buffer solution
was replaced at 15min intervals. Following equilibration, the tis-
sues were exposed to cumulatively increasing concentrations of
the inhibitory drugs (ﬁnal concentrations in the organ bath rang-
ing between 1 nM and 10μM). Three 5min washes followed by
three 15min washes with drug free Krebs–Henseleit solution were
performed between concentration–response curves of different
drugs permitting full recovery of the amplitude of neurogenic
contractions. In each experiment, two LM/MP preparations from
each test group of animals were studied simultaneously and the
responses of the tissues from the same animal averaged. The effect
of each agonist on the amplitude of the neurogenic contractions
was calculated as percent inhibition from the original amplitude.
Each of the agonists was alternated in sequence to reduce the
impact of the sequence of administration upon the calculated IC50
value. Geometric mean IC50 values were calculated and compared
among treatment groups as previously described (Taylor et al.,
1988).
The procedure outlined above was also used for experiments
using nicotine with the only difference being the absence of
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electrical stimulation since nicotine elicited contractions by stim-
ulating ganglionic release of acetylcholine. Nicotine (ﬁnal bath
concentrations ranging between 0.3 and 100μM) was added in
a non-cumulative manner with at least three 5-min washes per-
formed before the next drug concentration was added. Responses
were calculated in grams of tension or percent of the maxi-
mum contraction for that tissue. The values were used to deter-
mine the EC50 (i.e., concentration required to produce 50% of
the maximum response) and to calculate the maximum ten-
sion produced by nicotine. Computer assisted analysis of each
concentration–response curve using GraphPad Prism® software
(GraphPad Software, Inc.) was employed to determine the IC50 or
EC50.
Paw pressure mechanical analgesia assessment
Behavior assessment was performed between 9 and 10 AM on
the day of the experiment. Each animal was acclimated to the
observation room for 1 h prior to the initiation of any assessment.
The Randall and Selitto (1957) test was used to assess mechanical
nociception (Randall and Selitto, 1957). In this test, pressure was
manually applied to the plantar surface of the hind paw using a
cone-shaped pusher with a rounded tip. The force (g ) at which
the guinea pig withdrew its hind paw was deﬁned as the paw
pressure threshold. A cut-off was set at 600 g of pressure to pre-
vent tissue damage. Baseline analgesia was determined prior to
injecting the challenge drug. Subsequent mean response thresh-
olds were determined at the following time intervals after acute
drug administration: 15, 30, 45, 60, 90, and 120min. Tolerance
was deﬁned as a reduction in the antinociceptive effect (decreased
threshold for withdrawal) of the challenge dose of agonist such
that the maximum amount of pressure required to elicit a paw
withdrawal was decreased. The challenge dose employed (mor-
phine, 10mg/kg s.c.) was selected based on preliminary studies
done to assess the optimum dose required to produce an adequate
and quantiﬁable analgesic response. The magnitude of the toler-
ance that developed was assessed by calculating the area under the
curve (AUC) for the time versus latency response using GraphPad
Prism 5. There was no apparent difference in locomotor activity
displayed by the subjects in the treatment group in response to the
acute drug administration.
Hypothermia assessment
Assessment of body temperature using a rectal thermometer was
performed in a quiet room at an ambient temperature of 25˚C.
After a 1-h acclimatization period in the test room, body temper-
ature was measured using a digital rectal thermometer inserted
to a constant depth of 2.5 cm. Following thermometer insertion,
a 15-s equilibration period was allowed to lapse before the tem-
perature was recorded. Baseline rectal temperature was measured
twice prior to drug challenge (morphine 10mg/kg s.c.) and subse-
quently at 15, 30, 45, 60, 90, and 120min after drug administration.
The results were expressed as the mean± SEM of the change in
temperature (˚C) from baseline. The magnitude of the response
that developed was assessed by calculating the AUC for the time
versus latency response using GraphPad Prism 5. Tolerance was
deﬁned as a reduction in the maximum hypothermic effect of the
challenge dose of agonist.
DRUGS AND CHEMICALS
Morphine and placebo pellets were obtained from Dr. K. H. Davis
(Research Triangle Institute, Research Triangle Park, NC, USA)
through the National Institute on Drug Abuse (NIDA) inves-
tigator supply program. Each morphine pellet contained 75mg
morphine whereas a similar amount of lactose replaced morphine
in the placebo pellets. Morphine powder (morphine sulfate pen-
tahydrate salt), CADO (2-chloroadenosine), DAMGO ([d-Ala2,
N -Me-Phe4, Gly5-ol]-Enkephalin acetate), and nicotine (Nico-
tine hydrogen tartrate) were procured fromSigma-AldrichCo. (St.
Louis, MO, USA). For organ bath studies, solutions of DAMGO,
CADO, and nicotine were made by dissolving their respective
salts in distilled water. Parenterally administered morphine was
dissolved in normal saline.
DATA ANALYSIS
For the LM/MP organ bath experiments, the sensitivity of a group
of tissues to an inhibitory agonist was determined by calculating
themean negative log of the concentration producing 50% inhibi-
tion of the electrically induced contraction (IC50 ± SEM). Percent
inhibition was calculated using the mean contraction height at
the maximum inhibition following addition of a given concentra-
tion of agonist, divided by the average contraction height 1min
before exposure to the initial dose of that agonist. Differences in
sensitivity to a given agonist between two groups of tissues were
determined by comparing the geometric mean IC50 values and
the mean ratio of geometric mean IC50 values (calculated as the
mean antilog of the difference in IC50 values between the two
groups). For nicotine stimulation experiments, the EC50 (i.e., the
concentration of drug required to produce a contraction mag-
nitude equal to 50% of the maximum contraction obtained in
that tissue) and the maximal isometric tension developed were
determined and compared. Signiﬁcant differences between the test
and control groups were determined using unpaired Student’s “t”
test. Comparison of the magnitude of tolerance produced in each
model system was assessed by comparing the ratio of the mea-
surements obtained for the control:morphine treated group with
a probability level of ≤0.05 accepted as signiﬁcantly different.
Statistical analysis of drug–response data (in vivo and in vitro)
was performed using a two way ANOVA followed by followed by
Bonferroni post hoc test. The Student’s t -test (unpaired) was used
to compare the mean mechanical analgesia threshold between the
control and test groups and to compare the effects of the ago-
nists on body temperature. Tolerance was assessed by comparing
the maximal analgesic or hypothermic effect observed following
acute drug challenge. To assess the magnitude of tolerance, the
AUC for the control and the test groups was computed and the
control:morphine group AUC ratio was deﬁned as the magnitude
of tolerance. A p value≤ 0.05 was considered to be statistically
signiﬁcantly different.
RESULTS
ASSESSMENT OF THE MORPHINE-INDUCED HYPOTHERMIA
FOLLOWING CHRONIC DRUG TREATMENT
The acute hypothermic effect of morphine (10mg/kg body weight
s.c.) was determined by rectal body temperature assessment in
the same placebo and morphine pellet-implanted guinea pigs that
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were subjected to mechanical analgesia testing at various times
following implantation. Acute challenge with morphine resulted
in progressive hypothermia at an ambient temperature of 25˚C
that reached a maximum response between 60 and 90min after
administration. The hypothermic effect of morphine was modest
in magnitude and was not affected by the treatment (maximum
change in temperature for placebo group=−1.12± 0.16˚C ver-
sus −1.32± 0.16˚C for morphine group). Chronic exposure to
morphine did not produce tolerance at any time period depicted
(Figures 1A–D). Data obtained in animals at 7, 17, and 21 days
post-implantation also failed to demonstrate the development of
tolerance (data not shown). However, a small but statistically sig-
niﬁcant increase in mean body temperature was observed in ani-
mals that had been implanted for both 4 days (mean body temper-
ature= 39.4± 0.2˚C in placebo versus 40.1± 0.1˚C in morphine
animals) and 7 days (mean body temperature= 39.6± 0.1˚C in
placebo versus 39.9± 0.1˚C in morphine animals, p ≤ 0.05). Daily
assessment conﬁrmed that the change in body temperature was
not due to infection or obvious inﬂammation resulting from the
implantation procedure. As indicated in Table 1 and Figure 1E,
the ratio of AUC values for the hypothermic effect of morphine
between placebo andmorphine treated animalswas generally close
to unity and not statistically signiﬁcantly different at any time
period tested. Though morphine produced a modest hypother-
mia that was accompanied by wide variability, the data indicate
that no tolerance developed to that effect in animals chronically
implanted with morphine pellets.
ASSESSMENT OF THE MECHANICAL ANALGESIC RESPONSE
FOLLOWING CHRONIC DRUG TREATMENT
The analgesic effect of morphine (10mg/kg body weight s.c.) to
a mechanical stimulus was determined using the paw pressure
method (Randall and Selitto, 1957). The analgesic effect of mor-
phine was evident within 15–30min of drug administration and
persisted throughout the observation period (120min) with the
highest values of pressure required to elicit paw retraction rang-
ing from 400 to 600 g (Figures 2A–D). The maximum analgesic
effect was observed between 30 and 90min for both the placebo
FIGURE 1 | (A–D)The change in body temperature produced by an acute
challenge with morphine (10mg/kg) in guinea pigs implanted with either
placebo- or morphine-containing pellets at various time periods. Morphine
produced a modest hypothermia that was not apparently altered by
chronic treatment with morphine. (E)The calculated AUC values for the
hypothermic effect of morphine in guinea pigs implanted with morphine
pellets. The values were used to evaluate the total magnitude of the
response to morphine (10mg/kg). Ratios of AUC values were determined
and are presented inTable 1. Statistically signiﬁcantly different values are
indicated by (∗).
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Table 1 | Influence of morphine exposure for various time periods after pellet implantation on the ratio of hypothermic and analgesic responses
to morphine in vivo, maximum contractions to nicotine and inhibition of neurogenic twitches by DAMGO and 2-CADO of LM/MP preparations
in vitro.
Response measured Days after pellet implantation
1day 4days 10days 14days
INVIVO RESPONSES: RATIO OF MORPHINETO PLACEBOTREATED GROUP RESPONSE
Hypothermia AUC 1.13 (4) 0.7 (4) 0.7 (4) 0.82 (4)
Analgesia AUC 1.88* (4) 2.56* (4) 1.75* (4) 1.1 (4)
INVITRO EXCITATORY RESPONSES: RATIO OF MORPHINETO PLACEBOTREATED GROUP RESPONSE
Nicotine Maximum 0.74 (4) 1.41* (4) 1.93* (4) 1.31 (4)
INVITRO INHIBITORY RESPONSES: RATIO OF MORPHINETO PLACEBOTREATED GROUP RESPONSE
DAMGO IC50 values 2.08 (4) 4.0* (4) 3.3* (4) 2.4 (4)
2-CADO IC50 values 1.7 (4) 3.2* (4) 7.7* (4) 4.1* (4)
Values depict the ratio of morphine to placebo treated group response.
The same animals or preparations obtained from those animals were used in each experiment so sample sizes are identical (n=4) for each response being evaluated.
Values that are statistically signiﬁcant (p≤0.05) are indicated by ∗.
andmorphine groups.As illustrated in Figures 2A–C, signiﬁcantly
lower mechanical pressure was required to elicit a paw withdrawal
in the animals chronically exposed to morphine compared to the
placebo at 1, 4, and 10 days suggesting that tolerance had devel-
oped in response to the chronic morphine exposure and persisted
beyond a time when morphine plasma concentrations would be
expected to be very low. A similar reduction in threshold pres-
sure was observed in animals treated for 7 days (data not show).
In animals treated for 14 (Figure 2E) as well as 17 and 21 days
(data not shown), there was no reduction in mechanical pressure
threshold suggesting that the tolerance that developed between
days 1 and 10 had spontaneously declined by 14 days after pellet
implantation. The magnitude of tolerance developed as deter-
mined by the AUC values was statistically signiﬁcantly different
at 1–10 days but not at 14 (Figure 2E; Table 1), 17, or 21 days (data
not shown) post-implantation. These data suggest that the devel-
opment of tolerance to the analgesic effects of morphine occurs
over a time course that extends through at least 10 days and spon-
taneously recovers to normal levels between 10 and 14 days after
pellet implantation and remains constant beyond that time.
LM/MP ORGAN BATH ASSAY
Chronic exposure to morphine resulted in the development of
subsensitivity to both 2-chloroadenosine (CADO) and DAMGO
at 4, 7, and 10 days following pellet implantation (Tables 1 and 2).
As illustrated in Figure 3, concentration–response curves for the
inhibitory effect of DAMGO depict a signiﬁcant rightward shift
at 4 and 10 days but not at 1 or 14 days after pellet implantation.
The calculated geometric mean IC50 values of the morphine and
placebo groups revealed a signiﬁcant reduction in responsiveness
to both DAMGO and 2-CADO (Tables 1 and 2). As indicated by
the ratio of mean IC50 values presented in Table 2, the reduc-
tion in responsiveness increased in magnitude from day 4 to day
7 after implantation and, for DAMGO, began to decline after day
10 to return to values that were not statistically signiﬁcantly dif-
ferent by day 14. A similar reduction in responsiveness as shown
by the rightward shift of the concentration–response curves, was
observed with 2-CADO but the responsiveness remained reduced
even at 14 days after pellet implantation. These data suggest
that the development of reduced responsiveness (i.e., tolerance)
assessed in this in vitro model system develops slowly and pro-
gressively, and spontaneously reverses back to normal levels. The
calculated magnitude of rightward or loss of sensitivity shift (i.e.,
ratio of mean IC50 values) of the treated compared to the control
group was nearly fourfold for DAMGO and threefold for CADO
at 4 days and reached a maximum of seven- to eightfold for both
agonists 7 and 10 days after treatment (Tables 1 and 2). In addi-
tion, themaximum inhibitory effect for each agonist (ranged from
85± 5 to 100% of the twitch amplitude) at each time period and
was not statistically signiﬁcantly different between the treatment
groups as has been previously reported (Leedham et al., 1989).
The impact of chronic drug treatment on the contractile
response of the LM/MP to nicotine (Table 2) revealed no statisti-
cally signiﬁcant differences in the nicotine EC50 values following
chronic morphine treatment at any time period tested. However,
chronic morphine treatment did produce an elevation in themax-
imum response that was evident at 4 and 10 days but not at 1
and 14 days after pellet implantation (Figure 4). As indicated in
Table 1, the maximum response to nicotine increased by 1.4-fold
at 4 days and was elevated nearly twofold at day 10 suggesting that
the time period over which sensitivity to nicotine is increased lies
between 4 and 14 days of treatment.
DISCUSSION
The goal of these studies was to determine if the change in respon-
siveness observed in vitro correlates with changes assessed in vivo
following chronic exposure tomorphine. The results clearly afﬁrm
the proposed hypothesis. However, a corollary hypothesis pre-
dicted the time course of tolerance expressed in the in vitro LM/MP
preparation would be similar to that observed in an in vivo model
system. The results indicate that tolerance to the analgesic effect
of morphine can be deﬁned by a time course of development
and decline that is consistent with that observed in the LM/MP.
A clear correlation between the activity in the guinea pig LM/MP
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FIGURE 2 | (A–D)The analgesic effect produced by an acute morphine
(10mg/kg) administration in guinea pig implanted with either placebo- or
morphine-containing pellets at various time periods. Analgesia was measured
using the Randall–Sellito paw pressure test. (E)The calculated AUC values for
the analgesic effect of morphine in guinea pigs implanted with morphine
pellets.The values were used to evaluate the total magnitude of the response to
morphine (10mg/kg). Ratios of AUC values were determined and are presented
inTable 1. Statistically signiﬁcantly different values are indicated by (∗).
preparation model and analgesic activity of opioids in vivo has
been previously documented (Kosterlitz and Waterﬁeld, 1975).
The development of reduced responsiveness to both 2-CADO and
DAMGO, and the increased responsiveness to nicotine conﬁrm
earlier studies from several different laboratories demonstrating
the heterologous nature of the change induced by chronic mor-
phine treatment (Johnson et al., 1978; Taylor et al., 1988; Taylor
and Fleming, 2001).
Recent work from this laboratory (Li et al., 2010) deﬁned a sim-
ilar time course for the development of functional heterologous
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Table 2 | Geometric Mean EC50 and IC50 values for agonist-induced responses of the LM/MP from animals implanted with morphine or placebo
pellets for various times.
Days following implantation NICOTINE EC50 (−Log M) DAMGO IC50 (−Log M) 2-CADO IC50 (−Log M)
Placebo Morphine Ratio Placebo Morphine Ratio Placebo Morphine Ratio
1 6.07 (±0.21) 5.94 (±0.14) 1.34 8.11 (±0.15) 7.79 (±0.09) 2.08 7.27 (±0.06) 7.04* (±0.11) 1.69
4 6.05 (±0.23) 6.15 (±0.14) 0.79 7.96 (±0.07) 7.36* (±0.08) 3.98* 7.16 (±0.08) 6.65* (±0.06) 3.23*
7 5.90 (±0.16) 5.98 (±0.21) 0.83 8.03 (±0.09) 7.17* (±0.11) 7.24* 7.1 (±0.05) 6.32* (±0.07) 6.02*
10 6.23 (±0.24) 5.99 (±0.19) 1.74 7.61 (±0.13) 7.09* (±0.04) 3.31* 7.12 (±0.05) 6.23* (±0.10) 7.76*
14 6.01 (±0.21) 6.03 (±0.20) 0.95 7.74 (±0.09) 7.36 (±0.07) 2.40 6.88 (±0.11) 6.27* (±0.08) 4.07*
Sample sizes were 4 for each group at each time period.
Values that are signiﬁcantly different from placebo (p≤0.05) are indicated by ∗.
FIGURE 3 | Mean concentration–response curves illustrating the
effect of chronic morphine treatment on DAMGO-mediated
inhibition of neurogenic twitches in the LM/MP. Mean
concentration–response curves in tissues obtained from animals 1 day
(A), 4-days (B), 10-days (C), and 14-days (D) after pellet implantation
are shown. The magnitude of the degree of tolerance is assessed by
comparing the geometric mean IC50 values (Table 2). A p value of ≤0.05
was considered statistically signiﬁcant.
tolerance in the guinea pig LM/MP following a single pellet
implantation procedure. The fact that tolerance appears to develop
over a time course that ranges between>1 and<14 days suggests
an adaptive process induced by chronic morphine exposure that
ultimately regulates cellular excitability. Though desensitization
requires the presence of morphine, its maintenance does not. This
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FIGURE 4 |The effect of chronic morphine treatment on the mean
maximum responses of LM/MP preparations to nicotine. Statistically
signiﬁcant increases in the maximum response are identiﬁed by ∗. A p
value of ≤0.05 was considered statistically signiﬁcant.
notion is supported by the pharmacokinetics associated withmor-
phine pellet implantation which shows peak morphine plasma
concentrations by 4–6 h post-implantation that correlate to a
“dumping” phase when the maximum antinociceptive effect is
observed and gradually disappears over the next 36 h (Yoburn
et al., 1985). In addition, almost 25% of the total morphine dose
is absorbed within the ﬁrst 24 h. However, tolerance to the anal-
gesic effects remained robust and heterologous tolerance began to
develop in other response modalities by 4 days after implantation.
This time period certainly extends beyond the 36 h time frame
over which effective antinociceptive concentrations of morphine
were observed in other studies (Yoburn et al., 1985). Furthermore,
tolerance both in vivo and in vitro lasted beyond day 10 at which
time morphine should be absent from the plasma.
The development of tolerance to the action of DAMGO and 2-
CADO on neurogenic twitches of the LM/MP has been reported
in several different studies (Taylor et al., 1988; Leedham et al.,
1989; Li et al., 2010). While most investigators use a 7-day treat-
ment period, only a few have conducted extensive time course
studies to characterize the functional changes in responsiveness
(Leedham et al., 1989; Li et al., 2010). The data generated in
this current study conﬁrm the previous results and additionally
demonstrates that the change in responsiveness to 2-CADO per-
sisted well beyond the 14-day time period. This effect has not
previously been reported though Li et al. (2010) did observe a
signiﬁcant reduction in responsiveness beyond 14 days that spon-
taneously resolvedby21 days. Thedataprovided in this studydiffer
from those described by Leedham et al. (1989) who found total
reversal of tolerance at 14 days. Though no explanation is imme-
diately apparent for the difference in these results, it is certainly
possible that the development of tolerance beyond 14 days could
well be a function of the sample size. However, since no change
in responsiveness to DAMGO was observed and the enhanced
response to nicotine diminished at that time, the persistent change
in responsiveness to 2-CADO may be speciﬁc to that agonist since
2-CADO appears to produce a hyperpolarization of myenteric “S”
neurons through a mechanism that is distinctly different from
that of opioids (Meng et al., 1997). Thus, the continued reduc-
tion in responsiveness to 2-CADO may reﬂect the presence of
complex adaptive changes in response to chronic morphine treat-
ment (Taylor and Fleming, 2001). It is very likely that the adaptive
processes employed by a cell, tissue, or animal may differ depend-
ing upon the nature of the agonist (McPherson et al., 2010). In
spite of the apparent persistent change in responsiveness to 2-
CADO, the in vitro data appear to be consistent with previous
studies and suggest that the LM/MP model may be very useful to
evaluate the potential cellular mechanisms since it is predictive of
the desensitization observed in vivo.
The lack of tolerance to the hypothermic effect of morphine is
an intriguing observation that may be explained by one of several
possibilities. First, the hypothermic effect produced by morphine
is very modest in magnitude compared to that of other agents
such as cannabinoids (Maguma and Taylor, 2011). The essential
role of receptor activation that results in a robust physiological
response and adaptation responsible for the development of toler-
ance is well documented (Taylor and Fleming, 2001) and has been
further reinforced by previous studies showing that chronic use
of sub-effective doses of opioids does not induce tolerance (Welch
and Eads, 1999). The shallow hypothermic response observedwith
morphine may provide an insufﬁcient stimulus to trigger changes
in cell physiology that are expressed as heterologous tolerance
in this model. Alternatively, the modest hypothermia observed
upon morphine challenge may be due to the non-selective activa-
tion of mu- and kappa-opioid receptors which produce opposing
effects (Rosow et al., 1980) with the former inducing hyperther-
mia the latter hypothermia (Adler and Geller, 1987; Spencer et al.,
1988). Since the predominant effect observed was hypothermia, it
is reasonable to assume that the response was primarily kappa
receptor-mediated. The small but signiﬁcant increase in mean
body temperature at 4 and 7 days after pellet implantation could be
an adaptationby the animal to unopposed small chronic hypother-
mia created by activation of kappa receptors. It is also possible that
the change in body temperature could be due to altered responsive-
ness of the animal to the environmental temperature. Regardless of
the mechanism, the change in mean body temperature is relatively
minor (0.7˚C at 4 days and 0.3˚C at 7 days).
This difference in receptor engagement has important implica-
tions to the current results and the comparison of data obtained
in vivo versus data obtained in vitro. A similar circumstance
of multiple receptors exists in the cholinergic myenteric neu-
rons expressing both mu- and kappa-opioid receptors. Acti-
vation of either receptor population attenuates acetylcholine
release and subsequent inhibition of muscle contractions (Leed-
ham et al., 1991). However, the mechanism by which mu-opioid
receptor activation inhibits acetylcholine release is by hyperpo-
larizing the “S” neurons while kappa receptor inhibit release
by reducing the entry of calcium into the nerve terminals at
the neuromuscular junction (Cherubini and North, 1985; Sur-
prenant and North, 1985). This difference in the site and mech-
anism of action in response to mu- and kappa-opioid receptor
activation may be responsible for the absence of tolerance to
kappa-opioid receptor selective agonists in the LM/MP follow-
ing chronic morphine treatment (Leedham et al., 1991). The
possibility that the hypothermic effect in vivo may be due to
kappa-opioid receptor activation further supports the correla-
tion between data produced in the LM/MP with that observed
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in vivo. Hypothermia secondary to kappa-opioid receptor activa-
tion also suggests the potential existence of an adaptive change
through membrane-potential mediated modiﬁcation of cellular
excitability.
The enhanced responsiveness to nicotinic receptor activation
7 days after morphine pellet implantation has been observed by
a number of laboratories (Goldstein and Schulz, 1973; John-
son et al., 1978). However, no studies have evaluated the time
course of the development of the change in responsiveness to
determine whether the enhanced responsiveness shared a similar
onset and decay as that observed for inhibitory agents (Leedham
et al., 1989; Li et al., 2010). The observation that changes in cel-
lular responsiveness to the excitatory effect of nicotine develop
over a similar time course to the reduced responsiveness to both
DAMGOandCADO in the LM/MPpreparation further reinforces
the idea that the adaptive change following chronic morphine
treatment involves a modiﬁcation in the membrane potential of
myenteric“S”neurons (Meng et al., 1997). This enhanced sensitiv-
ity to excitatory agents and reduced responsiveness to inhibitory
agents has been one of the foundations deﬁning the heterol-
ogous nature of opioid tolerance (Goldstein and Schulz, 1973;
Johnson et al., 1978). However, enhanced responsiveness develops
to agents that depolarize myenteric “S” neurons such as acetyl-
choline, serotonin, and nicotine and potassium but not to GABA
and muscimol that produce contraction but do not depolarize
“S” neurons (Goldstein and Schulz, 1973; Johnson et al., 1978;
Leedham et al., 1992). The close correlation of the time course
of reduced functional responsiveness to inhibitory agents and the
reduction in the abundance of the α3 subunit of the ubiquitous
Na+, K+-ATPase has been suggested to be the basis for the devel-
opment of tolerance (Leedham et al., 1992; Kong et al., 1997;
Biser et al., 2002; Li et al., 2010). It is tempting to speculate that
these two distinct observations may be related and that the adap-
tive change in responsiveness deﬁned by the altered excitability of
myenteric neurons is related to the depolarization associated with
the loss of electrogenic sodium pumping (Taylor and Fleming,
2001).
The results of these experiments indicate that the change in
responsiveness to nicotine does develop and decay over a time
course that is very similar to that seen with both other in vitro
assessments of tolerance as well as in vivo evaluation of toler-
ance. The close correlation between the enhanced responsiveness
tonicotine, the reduced response tomultiple inhibitory agents seen
in the current studies and the reduction in sodium pump alpha3
subunit isoform provide a very strong circumstantial case for a
functional relationship between these changes. The reduction in
sodium pump abundance would lead to a membrane depolariza-
tion of excitable cells which would increase the responsiveness to
excitatory agents like nicotine and serotonin and reduce respon-
siveness to inhibitors like DAMGO and 2-CADO. Furthermore,
the data obtained support the hypothesis that functional assess-
ment of the development of tolerance in vivo may share many
common elements to that observed in vitro. In addition, the results
of these studies support the idea that data assessing the mech-
anism(s) of development of tolerance obtained in the in vitro
LM/MP preparation may be predictive of potential mechanisms
that are responsible for the development of tolerance assessed
using in vivo models.
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